


Innovative Medicines Initiative: Ebola+ programme

Magda Chlebus
Director Science Policy
Paris, 10 March 2015



European Union's mobilisation



Ebola: the challenges



- * Evolving epidemic
- * No treatment/vaccines and no rapid diagnostics for use in the field
- * Rapid scaling up of candidate vaccine doses needed is difficult;
- * Current vaccine candidates require very cold temperatures for stability during transport;
- * Deployment (reaching those most in need) is challenging;
- * Adherence to vaccination regimens is challenging;
- * Range of products needed for current and future outbreaks.

Industry response: beyond competition



- * Engage with national health agencies
- * Engage with national and international research funding organisations to accelerate R&D of products that can impact on the current epidemics
- * Join forces across companies
 - * Screening all companies portfolios to identify suitable antiviral candidates
 - * Innovative Medicines Initiative
- * Global coordination

EU Research funding mechanisms: 17 Ebola projects



* When?

- * As soon as WHO rang the alarm bell


* What?

- * Vaccines, Therapeutics, Diagnostics
- * Basic research, Preparedness, Social sciences

* How?

- * Horizon 2020
- * **Innovative Medicines Initiative**
- * Framework Programme 7


Innovative Medicines Initiative – Europe’s partnership for health



Ebola+ programme overview

From Idea to Project start = 2-4 months !!

IMI2 Ebola and other filoviral haemorrhagic fevers programme Joint Information repository, Scientific Advisory Board, Ethics Board



**Total budget:
€ 215 million**

Why the Innovative Medicines Initiative ?

Collaboration between stakeholders and disciplines is a MUST to address the threat

Vaccinologists, infectious disease specialists, anthropologists, novel technologies, diagnostics, private industry

A neutral trusted platform facilitates exchange and helps align stakeholder's interests

A concerted international effort



And many more...

Summary



- * Massive, flexible and fast industry response
- * International coordination and collaboration: avoiding overlaps, align with WHO steer
- * Joining forces:
 - * Across companies and sectors
 - * Across public and private sectors
 - * Across borders
- * Continued effort – current and future epidemics